U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 71 - 80 of 571 results

Status:
Investigational
Source:
INN:peraquinsin
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Peraquinsin is an antihypertensive agent.
Status:
Investigational
Source:
INN:podilfen
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Podilfen is the vasodilator. It was used as an antihypertensive agent.
Status:
Investigational
Source:
INN:teopranitol [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Teopranitol, a coronary vasodilator that was studied for the treatment of the acute myocardial ischemia. Animal experiments have shown that this compound stimulated the release of prostacyclin (PGI2)-like antiplatelet activity. However, the development of teopranitol was discontinued.
Status:
Investigational
Source:
INN:morocromen [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Morocromen is an oxobenzopyranyl derivative patented by Troponwerke Dinklage und Co. as the coronary dilating agent.
Status:
Investigational
Source:
INN:butobendine [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Butobendine is trihydroxybenzoic acid derivative with marked antiarrhythmic activities in rats and cats.
Status:
Investigational
Source:
INN:perfomedil
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Perfomedil is a vasodilator. Perfomedil is a buflomedil analog. Perfomedil like its parent compound buflomedil, antagonizes both alpha1- and alpha2-adrenoceptors. An important difference between perfomedil and its parent compound is the preferential antagonism exerted against alpha2-adrenoceptors. In the saphenous vein of the dog perfomedil acts as a relatively weak alpha-adrenergic blocker in vascular smooth muscle, with a preferential effect on postjunctional alpha2-adrenoceptors. At the adrenergic nerves, the compounds inhibit prejunctional alpha2-adrenoceptors and displace stored transmitter.
Status:
Investigational
Source:
INN:sampatrilat
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Sampatrilat (also known as UK 81252) was developed as a dual inhibitor of both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). This drug was studied for the treatment of hypertension and congestive heart failure.
Status:
Investigational
Source:
INN:guanoxyfen
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Guanoxyfen sulfate is an antidepressant, antihypertensive. Guanoxyfen sulfate is an inhibitor of vasoconstrictor responses to sympathetic nerve stimulation. It could potentiate the actions of adrenaline and noradrenaline. It also could increase the blood glucose concentration and decrease the appetite.
Status:
Investigational
Source:
INN:enalkiren
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Enalkiren (A-64662) is a potent, dipeptide renin inhibitor, mimics the transition state of the human renin substrate, angiotensinogen. The results of clinical trials with enalkiren suggest that renin inhibitors may be safe, useful therapeutic agents in the management of hypertension. In addition, it exerts intraocular pressure lowering pressure. Enalkiren development for the treatment of glaucoma, heart failure, hypertension has been discontinued.
Status:
Investigational
Source:
INN:mopidralazine
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Mopidralazine is slower in onset and longer lasting than hydralazine and is devoid of adrenergic system stimulation. Its antihypertensive action is mediated by arteriolar dilatation. In the rat, Mopidralazine is rapidly metabolized, mainly by pyrrole-ring opening and subsequent formation of a mesoionic 3-(1-pyridazinyl)pyridazine In dogs, oxidative cleavage of the morpholine ring has been found to be the primary metabolic attack. In a small clinical trial, Mopidralazine resulted in significant reductions in blood pressure, both supine and standing, which was maximal 4-8 h after dosing, with no additional orthostatic component.